ReviewDrug safety2012
Benefit-risk assessment of bevacizumab in the treatment of breast cancer.
Rodrigo Dienstmann et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it
ReviewDrug safety2012
Rodrigo Dienstmann et al.PubMed ↗Publisher ↗
No numbers read from the abstract.